Successful Treatment of Life-Threatening Small Bowel Bleeding With Thalidomide After Living Donor Kidney Transplantation: A Case Report

Transplant Proc. 2019 Nov;51(9):3092-3098. doi: 10.1016/j.transproceed.2019.07.009. Epub 2019 Oct 14.

Abstract

Gastrointestinal bleeding after kidney transplantation is a complication that can occur from immunosuppressant use. We present a case of refractory small bowel bleeding treated successfully with thalidomide after multiple failed attempts of conventional treatment. A 65-year-old male patient with diabetic nephropathy underwent living donor kidney transplantation. The surgery was uneventful, however, he developed immunosuppressant-induced melena with unstable vital signs 11 days later. There were a total of 4 bleeding episodes until the 90th postoperative day, and he received a total of 290 units of red blood cell transfusion during this period. Endoscopic clipping, transarterial embolization, and 2 surgical interventions failed to stop the bleeding. A trial of thalidomide 100 mg per day finally stopped the bleeding and the patient was discharged on the 110th postoperative day with a functioning renal graft. This case shows that thalidomide can be a safe option to treat immunosuppressant-induced refractory gastrointestinal bleeding in the setting of kidney transplantation. Additionally, this is the first case that reports the survival of a renal graft after more than 3000 mL of transfusion.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / therapeutic use*
  • Gastrointestinal Hemorrhage / drug therapy*
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Kidney Transplantation / adverse effects*
  • Living Donors
  • Male
  • Melena / immunology
  • Middle Aged
  • Postoperative Complications / drug therapy*
  • Postoperative Complications / etiology
  • Tacrolimus / adverse effects
  • Thalidomide / therapeutic use*

Substances

  • Angiogenesis Inhibitors
  • Immunosuppressive Agents
  • Thalidomide
  • Tacrolimus